Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $130.00 Price Target at Needham & Company LLC

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective trimmed by Needham & Company LLC from $139.00 to $130.00 in a research note released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

RYTM has been the topic of several other research reports. Wells Fargo & Company boosted their price target on shares of Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Citizens Jmp raised their price objective on Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. TD Cowen reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Morgan Stanley decreased their target price on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Canaccord Genuity Group dropped their price target on Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.75.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM opened at $87.68 on Tuesday. The firm has a market cap of $5.99 billion, a P/E ratio of -28.19 and a beta of 2.06. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20. The company has a 50 day simple moving average of $99.77 and a two-hundred day simple moving average of $102.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The firm had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. During the same quarter in the previous year, the firm earned ($0.72) earnings per share. The company’s quarterly revenue was up 36.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the sale, the chief accounting officer directly owned 160 shares of the company’s stock, valued at approximately $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 27,267 shares of company stock valued at $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its position in shares of Rhythm Pharmaceuticals by 303.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after acquiring an additional 200 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares during the period. SBI Securities Co. Ltd. grew its stake in Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Rhythm Pharmaceuticals by 48.6% during the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares during the period.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company delivered solid revenue growth and a Q4 beat (FY25 revenue $194.8M, +50% year/year), which supports continued commercial demand for IMCIVREE (setmelanotide) and underpins longer-term upside. Article Title
• Positive Sentiment: Company highlights post‑hoc analyses showing statistically significant BMI reductions at 52 weeks in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants — these subgroup signals could support label expansion or targeted use, which investors may view as constructive if regulators/market accept the evidence. Article Title
• Neutral Sentiment: Company-hosted transcript and slide materials on the EMANATE topline results are available for investors evaluating the detailed data and management commentary; these provide context for both the misses and the subgroup findings. Transcript Slides
• Negative Sentiment: Topline EMANATE results showed the experimental obesity program did not meet several pre‑specified primary endpoints across four substudies — the primary failure is the main driver of near‑term negative sentiment and regulatory scrutiny. Reuters
• Negative Sentiment: Multiple major brokerages trimmed price targets today (Citigroup, RBC, Citizens JMP, BofA, Morgan Stanley, Needham). Although most retained buy/outperform ratings, the lower targets signal reduced near‑term upside expectations and likely contributed to selling pressure. Benzinga TickerReport

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.